Grassley and Bipartisan Drug Affordability Cosponsors Urge FDA Commissioner to Reform Anticompetitive Drug Practices

WASHINGTON – Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) alongside Senators Patrick Leahy (D-Vt.), Mike Lee (R-Utah), and Amy Klobuchar (D-Minn.) are asking Food and Drug Administration (FDA) Commissioner Scott Gottlieb to address anticompetitive practices currently used by some brand-name pharmaceutical companies to delay the manufacture and introduction of generic drugs in the market. Commissioner Gottlieb recently outlined his concerns with such abusive practices, which would be addressed by the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, introduced by the authors of today’s letter and other senators.

 

The letter will be included in the record as part of the FDA’s public meeting about innovation in drug development and access to affordable drugs titled “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” The letter discusses abuses of Risk Evaluation Mitigation Strategy (REMS) programs by certain brand-name pharmaceutical companies and urges Commissioner Gottlieb to consider using FDA’s authority to more readily waive the requirement for a single, shared REMS if, after a good faith effort or a reasonable amount of time, a generic drug company has submitted a separate proposal that satisfies REMS requirements. It also cites the need for Congressional action to pass the CREATES Act.

 

 

The CREATES Act combats anticompetitive practices used by some brand-name pharmaceutical and biologic companies to block the entry of lower-cost generic drugs in the market. The legislation would deter pharmaceutical companies from denying samples to generic companies for product testing and gives the FDA more flexibility to make determinations with respect to single REMS distribution systems.

 

Full text of the letter is below, and a pdf can be found here. An outline of the CREATES Act can be found here, and text of legislation can be found here.

 

 

 

July 20, 2017

 

The Honorable Scott Gottlieb, M.D.

Commissioner

U.S. Food and Drug Administration

5630 Fishers Lane

Room 1061

Rockville, MD 20852

 

Re: Docket # FDA-2017-N-3615 for “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments”

 

Dear Commissioner Gottlieb:

 

Thank you for holding the public meeting on July 18, 2017, “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access,” to ensure the balance between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives. We appreciate your leadership and efforts to raise awareness about how the FDA’s rules are being used to decrease competition and delay the entry of generic drugs into the market.

 

Since enactment of Hatch-Waxman, patients have benefited from increased access to safe, affordable, and high quality generic medicines. However, the critical balance between innovation and access is jeopardized by current abuses and manipulation of the regulatory process. As you recognized in your recent testimony before the Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, “The bottom line is that there is no question there are places where companies do take advantage of rules meant for one purpose as a way to gain commercial advantage.”^[1]

 

We agree with your concern that some companies are manipulating the Risk Evaluation Mitigation Strategy (REMS) programs to delay generic competition. To alleviate this problem, we have introduced the CREATES Act (S.794), which addresses two abuses of the REMS program while maintaining current patient safety standards and helping to lower prescription drug costs. The REMS issue is well understood, and the CREATES Act provides a simple and effective solution.

 

Certain branded companies are currently preventing generic competitors from obtaining branded samples. Without access to these branded samples, a generic company cannot conduct the testing necessary to receive FDA approval, delaying lower-cost competition that would benefit consumers. Just last year, the FDA reported that it had received more than 150 inquiries from generic drug companies unable to obtain samples needed for bioequivalence testing.^[2] The FDA also noted, “Many of these brand drug products are quite expensive. A significant majority of these drug products are listed online at a retail price of over $600 per patient per month, and many are in the range of thousands of dollars per patient per month.”^[3]

 

Some companies argue that certain REMS, which limit how a prescription drug is distributed (known as Elements to Assure Safe Use, or “ETASU”) prevent the sale of the product to a generic company. The FDA rightly rejected this justification. The purpose of an ETASU is to protect patients, not to prevent potential competitors from obtaining needed samples.

 

The CREATES Act would address this issue by creating a narrow remedy that generic companies could use to quickly obtain samples when a branded company abuses the regulatory process in this manner. In the case of drugs subject to limited distribution requirements, our legislation maintains current safety protections for bioequivalence testing, which the FDA has said are adequate.

Under current law, if a REMS requires an ETASU, there is a presumption that a generic manufacturer and the brand should use the same REMS, which is known as a single, shared REMS. The FDA may waive the requirement and approve a separate system for the generic product if the burden of creating a single, shared system outweighs the benefit of a separate system. As a practical matter, until the branded and generic companies agree to a single, shared system or the FDA waives that requirement, the generic company cannot receive approval. Meanwhile, the branded company, under the previously approved REMS, continues to maintain a monopoly and sell its product without facing generic competition.

 

The longer branded companies delay reaching an agreement on single, shared systems, the longer they avoid competition and deny consumers cost-saving alternatives. In nearly a decade since Congress created this system, to our knowledge, only one branded company has reached agreement on a single, shared REMS prior to the generic company receiving FDA approval. The FDA has approved five other single, shared REMS, but in those cases, the REMS was required after both the branded and generic company were approved and on the market. This pattern suggests that when branded companies are not benefiting by extending negotiations, it is easier to reach agreement on a single, shared REMS. In addition, there are now 11 single, shared REMS systems in negotiations, “many of which involve the costliest medications to patients and to Medicare spending as a whole.” In all but one of these negotiations, the parties have missed at least one of the milestones set by the FDA. In January, the FDA waived the single, shared REMS requirement for a product after four years of failed negotiations.^[4]

The CREATES Act provides a narrow and simple solution to this second abuse. It would eliminate the presumption of a single, shared REMS, and the associated unintended incentives to delay competition. Instead, the FDA would be authorized to either approve a single system for the generic product that meets the same, safety requirements as the branded company’s system or require a single, shared REMS when necessary. This approach does not change the safety requirements for generic drugs subject to a REMS.

 

One of the regulatory issues on which we encourage you to take action is with respect to whether the FDA can waive the requirement for a single, shared REMS “more readily” than it has in the past. In particular, we urge you to consider implementing a framework in which the FDA would waive a single, shared REMS if, after a good faith effort or a reasonable amount of time, the generic company has submitted a separate proposal that satisfies the legal requirements for a REMS.

 

While we look forward to hearing more from you about what regulatory actions you believe the FDA can take to address strategies that prevent generics from obtaining samples needed for required regulatory testing and abuses in the REMS program, we believe Congressional action on the CREATES Act is necessary and an essential part of the solution to ending these abuses. We would welcome the opportunity to work with you on this legislative solution.

 

Thank you again for your attention to these issues. We look forward to working with you to promote safe, effective, and affordable drug prices by fostering greater competition.

 

Sincerely,

 

-30-

---